In the October 29, 2014, Federal Register, FDA announced the establishment of a docket to receive suggestions, recommendations, and comments from interested parties, including academic institutions, regulated industry, and other interested organizations on best practices for communication between FDA and investigational new drug application ("IND") sponsors during drug development. FDA says it intends to issue draft guidance in the future on this topic. Comments due December 29, 2014.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.